| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 109,052 | 91,107 |
| Proceeds from issuance of common stock, net of issuance costs | 0 | 0 |
| Proceeds from issuance of common stock under the atm, net of issuance costs | 19,382 | - |
| Proceeds from exercise of options and employee stock purchase plan purchases | 2,158 | 1,802 |
| Net cash provided by financing activities | 21,540 | 1,802 |
| (decrease) increase in cash, cash equivalents and restricted cash | -34,169 | -17,597 |
| Cash and cash equivalents at beginning of period | 142,083 | - |
| Cash and cash equivalents at end of period | 107,914 | - |
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)